Replidyne commences Phase I for REP8839
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Replidyne's topical anti-infective candidate REP8839 has begun Phase I studies, the firm says July 18. Replidyne, which recently filed an initial public offering registration statement, submitted an IND for the agent in May (1Pharmaceutical Approvals Monthly July 2006, p. 3)...
You may also be interested in...
Replidyne Orapem Antibiotic Likely To Need Additional Trials Before Approval
Replidyne is conducting an additional Phase III trial of its oral beta-lactam antibiotic Orapem in anticipation of an FDA request for additional studies, according to the firm’s initial public offering prospectus.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.